Navigation Links
IDRI and Chembio Collaborate to Develop a Low-Cost Test for Visceral Leishmaniasis

SEATTLE and NEW YORK, May 11 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) and Chembio Diagnostics Systems, Inc. (Chembio) today announced they have entered into a milestone-based agreement pursuant to which Chembio will use its patented dual path platform technology (DPP(R)) and other Chembio capabilities to design, develop and manufacture a low-cost device for the diagnosis of visceral leishmaniasis. This step is critical to IDRI's program funded under a grant from the Bill & Melinda Gates Foundation for the development of accurate, rapid and affordable methods of diagnosis for patients suffering from visceral leishmaniasis in Africa. This announcement was made at the 96th Annual Meeting of the American Association of Immunologists (Immunology 2009) held May 8-12 in Seattle, WA.

Most visceral leishmaniasis cases occur in poor populations living in remote areas far from healthcare centers. In these settings, the disease often co-exists with malaria and other debilitating parasitic infections that exhibit similar symptoms, making diagnosis difficult. In these challenging conditions, the traditional labor-intensive and complex diagnostic procedures -- invasive removal of bone marrow, spleen and lymph node tissues for microscopic examination and isolation of the parasite by culture -- are neither feasible nor field-friendly.

"We are actively working to develop a rapid and simple test that could be used in the field in Africa to diagnose visceral leishmaniasis by using no more than a drop of blood," said Dr. Steven Reed, Founder and Head of IDRI's Research and Development Program. "This would dramatically improve early detection of visceral leishmaniasis, making current treatments more effective and decreasing transmission rates."

Rapid diagnostic tests are made of two major components: the reagents which are selected to react with specific immunologic components present in the blood of infected patients, and the device which acts as a physical support for the reagents. Diagnostic devices can be as simple as strips of paper or plastic cassettes. These simple tests do not require highly skilled laboratory staff and can be done in the field with results usually available within the next ten to fifteen minutes.

Curt Malloy, SVP Operations and General Counsel of IDRI said, "Chembio has significant experience in the development, manufacturing and distribution of diagnostic tests, particularly in the developing world. IDRI will provide the reagents for the test and, with our financial support, Chembio will develop a reliable diagnostic device that can be manufactured at low-cost. This will be paramount to ensure affordability of the test when ready for implementation."

"We are thrilled to be able to collaborate with IDRI on the complex yet urgent task of controlling visceral leishmaniasis in developing countries," commented Larry Siebert, Chairman and President of Chembio. "Working alongside IDRI, we will apply our DPP(R) and other technologies to create a low-cost diagnostic device to help fight this disease that has been ignored for too many years," commented Javan Esfandiari, Senior Vice President of R&D for Chembio.

About Visceral leishmaniasis

Visceral leishmaniasis (VL) is a serious, potentially lethal, systemic parasitic illness that has caused epidemics in India, Southeast Asia, Africa and Latin America. Leishmania parasites are transmitted to humans through the bite of infected sandflies. Patients with VL develop infections of their liver, spleen, and bone marrow and may die if the infection goes untreated. About 500,000 new cases of visceral leishmaniasis occur each year, and 10% of these patients -- mostly children -- die because their disease cannot be accurately diagnosed in a timely fashion.

IDRI-Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most. For more information, go to

IDRI has been working on leishmaniasis for more than 15 years, applying its expertise to the development of both vaccines and diagnostics. IDRI is actively developing a therapeutic leishmaniasis vaccine designed to be used in conjunction with chemotherapy. This candidate vaccine is currently being tested in several countries. If successful, both diagnostic and therapeutic tools would complement each other to provide an improved strategy against leishmaniasis.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Inverness Medical. Chembio markets its HIV STAT-PAK(R) line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and Chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform (DPP(R)) technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP(R). Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.

SOURCE Infectious Disease Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cleveland Clinic, University Hospitals and MetroHealth Collaborate on Free Medical Clinic May 2-3
2. Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
3. AORN and Mercy Ships Collaborate to Increase Patient Care Aboard Hospital Ships
4. Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings
5. Genstruct and Gene Logic Collaborate on Systems Toxicology
6. Impac Software Collaborates With the National Comprehensive Cancer Network to Improve Patient Care
7. Pharmacy Stakeholder Groups Collaborate to Draft Pharmacy Principles for Health Care Reform
8. Collaborate and Converse on HIMSS E-Prescribing Wiki
9. KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times
10. NCCN and SEHA Collaborate to Improve Cancer Care
11. Healthbase Collaborates with WellPoint to Bring Affordable Medical Tourism Solutions
Post Your Comments:
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announced it has been awarded a fixed price per sprint agile development contract ... valued at $34 million over five years, provides software engineering, infrastructure, as well ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 ... tecnología para cuchillas de precisión, develó hoy ... de identidad de marca. El nuevo logo ... diseño y la ingeniería de productos con ... diferencia". ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
Breaking Medicine Technology: